Squarepoint’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-130,066
| Closed | -$16.7M | – | 4383 |
|
|
2025
Q2 | $16.7M | Buy |
130,066
+104,960
| +418% | +$10.9M | 0.02% | 853 |
|
|
2025
Q1 | $2.22M | Sell |
25,106
-240,314
| -91% | -$23.4M | ﹤0.01% | 2013 |
|
|
2024
Q4 | $23.1M | Buy |
265,420
+41,210
| +18% | +$3.77M | 0.02% | 704 |
|
|
2024
Q3 | $20.7M | Buy |
+224,210
| New | +$22.3M | 0.03% | 580 |
|
|
2024
Q1 | – | Sell |
-3,246
| Closed | -$278K | – | 4059 |
|
|
2023
Q4 | $299K | Buy |
+3,246
| New | +$210K | ﹤0.01% | 3359 |
|
|
2023
Q2 | – | Sell |
-63,989
| Closed | -$2.88M | – | 3586 |
|
|
2023
Q1 | $2.88M | Buy |
63,989
+48,526
| +314% | +$2.19M | 0.01% | 1184 |
|
|
2022
Q4 | $677K | Sell |
15,463
-11,082
| -42% | -$531K | ﹤0.01% | 2091 |
|
|
2022
Q3 | $1.75M | Sell |
26,545
-44,108
| -62% | -$2.83M | 0.01% | 1405 |
|
|
2022
Q2 | $3.57M | Buy |
70,653
+62,471
| +764% | +$3.66M | 0.02% | 857 |
|
|
2022
Q1 | $523K | Sell |
8,182
-5,205
| -39% | -$374K | ﹤0.01% | 1977 |
|
|
2021
Q4 | $1.43M | Buy |
+13,387
| New | +$1.4M | ﹤0.01% | 1466 |
|
|
2020
Q4 | – | Sell |
-14,426
| Closed | -$1.34M | – | 2931 |
|
|
2020
Q3 | $1.34M | Sell |
14,426
-13,281
| -48% | -$1.02M | 0.02% | 837 |
|
|
2020
Q2 | $2.16M | Buy |
+27,707
| New | +$1.87M | 0.04% | 610 |
|
|
2019
Q4 | – | Sell |
-27,810
| Closed | -$2.04M | – | 2492 |
|
|
2019
Q3 | $2.04M | Buy |
27,810
+7,147
| +35% | +$618K | 0.02% | 839 |
|
|
2019
Q2 | $1.95M | Sell |
20,663
-14,224
| -41% | -$1.17M | 0.02% | 865 |
|
|
2019
Q1 | $2.79M | Buy |
34,887
+27,272
| +358% | +$2.02M | 0.03% | 636 |
|
|
2018
Q4 | $411K | Sell |
7,615
-1,285
| -14% | -$78.1K | ﹤0.01% | 1354 |
|
|
2018
Q3 | $695K | Buy |
8,900
+5,400
| +154% | +$375K | 0.01% | 1154 |
|
|
2018
Q2 | $222K | Buy |
+3,500
| New | +$279K | ﹤0.01% | 1499 |
|
|
2018
Q1 | – | Sell |
-7,950
| Closed | -$600K | – | 1709 |
|
|
2017
Q4 | $600K | Buy |
+7,950
| New | +$559K | 0.01% | 1097 |
|
|
2017
Q3 | – | Sell |
-10,700
| Closed | -$542K | – | 1622 |
|
|
2017
Q2 | $542K | Buy |
10,700
+594
| +6% | +$25.2K | 0.01% | 922 |
|
|
2017
Q1 | $404K | Buy |
10,106
+2,306
| +30% | +$82.6K | 0.01% | 950 |
|
|
2016
Q4 | $219K | Buy |
+7,800
| New | +$235K | 0.01% | 1372 |
|
Other funds holding BPMC
IA
HNB
Squarepoint's BPMC Position: Q3 2025 in Review
Squarepoint sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 130,066 shares — an estimated $16.7M sold.
Squarepoint first reported a position in BPMC in Q4 2016 and held it in 23 quarters. The position peaked at $23.1M in Q4 2024. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.
- Squarepoint reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
- Squarepoint sold 130,066 Blueprint Medicines shares in Q3 2025, an estimated $16.7M.
- Squarepoint first reported a position in Blueprint Medicines in Q4 2016 and held it in 23 quarters.
- Squarepoint's Blueprint Medicines position peaked at $23.1M in Q4 2024.
- 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.
Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.